SABCS and ASH findings: palbociclib improves PFS in HR+, HER2+ breast cancer, cilta-cel achieves 100% CR in smoldering MM, and selinexor with ruxolitinib aids myelofibrosis.
It’s nearly time for championship week! We’re done looking forward; instead, we're and looking at which players can help us right now. Recent weeks have brought forth some big repeat performances from ...
Some results have been hidden because they may be inaccessible to you